{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:19:38Z","timestamp":1793312378249,"version":"4.5.0"},"reference-count":189,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objective<\/jats:title>\n                    <jats:p>Genomic medicine offers an unprecedented opportunity to improve cancer outcomes through prevention, early detection and precision therapy. Health policy makers worldwide are developing strategies to embed genomic medicine in routine cancer care. Successful translation of genomic medicine, however, remains slow. This systematic review aims to identify and synthesise published evidence on the cost effectiveness of genomic medicine in cancer control. The insights could support efforts to accelerate access to cost-effective applications of human genomics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study protocol was registered with PROSPERO (CRD42024480842), and the review was conducted in line with Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) Guidelines. The search was run in four databases: MEDLINE, Embase, CINAHL and EconLit. Full economic evaluations of genomic technologies at any stage of cancer care, and published after 2018 and in English, were included for data extraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The review identified 137 articles that met the inclusion criteria. Most economic evaluations focused on the prevention and early detection stage (\n                      <jats:italic>n<\/jats:italic>\n                      = 44; 32%), the treatment stage (\n                      <jats:italic>n<\/jats:italic>\n                      = 36; 26%), and managing relapsed, refractory or progressive disease (\n                      <jats:italic>n<\/jats:italic>\n                      = 51, 37%). Convergent cost-effectiveness evidence was identified for the prevention and early detection of breast and ovarian cancer, and for colorectal and endometrial cancers. For cancer treatment, the use of genomic testing for guiding therapy was highly likely to be cost effective for breast and blood cancers. Studies reported that genomic medicine was cost effective for advanced and metastatic non-small cell lung cancer. There was insufficient or mixed evidence regarding the cost effectiveness of genomic medicine in the management of other cancers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review mapped out the cost-effectiveness evidence of genomic medicine across the cancer care continuum. Gaps in the literature mean that potentially cost-effective uses of genomic medicine in cancer control, for example rare cancers or cancers of unknown primary, may be being overlooked. Evidence on the value of information and budget impact are critical, and advancements in methods to include distributional effects, system capacity and consumer preferences will be valuable. Expanding the current cost-effectiveness evidence base is essential to enable the sustainable and equitable translation of genomic medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40258-025-00949-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:08:16Z","timestamp":1743743296000},"page":"359-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-9771","authenticated-orcid":false,"given":"Mackenzie","family":"Bourke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aideen","family":"McInerney-Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Boughtwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne","family":"Milch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Laura","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ambrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Dalziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccarda","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Santos","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Goranitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"949_CR1","first-page":"20182020","volume-title":"Global cancer observatory: cancer today","author":"J Ferlay","year":"2020","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2020. p. 20182020."},{"key":"949_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"SC Shah","year":"2019","unstructured":"Shah SC, Kayamba V, Peek RM, Jnr., et al. Cancer control in low- and middle-income countries: is it time to consider screening? J Glob Oncol. 2019;5:1\u20138.","journal-title":"J Glob Oncol."},{"issue":"1","key":"949_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A, et al. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"949_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","volume":"15","author":"MF Berger","year":"2018","unstructured":"Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15(6):353\u201365.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"949_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40142-021-00200-7","volume":"9","author":"LM Seed","year":"2021","unstructured":"Seed LM. Horizon scanning in cancer genomics: how advances in genomic medicine will change cancer care over the next decade. Curr Genet Med Rep. 2021;9(3):37\u201346.","journal-title":"Curr Genet Med Rep."},{"issue":"5","key":"949_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.2140","volume":"1","author":"K Manickam","year":"2018","unstructured":"Manickam K, Buchanan AH, Schwartz MLB, et al. Exome sequencing-based screening for BRCA1\/2 expected pathogenic variants among adult Biobank participants. JAMA Netw Open. 2018;1(5): e182140.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"949_CR7","first-page":"1441","volume":"3","author":"R Kelsey","year":"2022","unstructured":"Kelsey R. Genomics guides targeted therapy. Nat. Cancer. 2022;3(12):1441.","journal-title":"Cancer"},{"issue":"1","key":"949_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s44178-024-00099-4","volume":"3","author":"D Chaji","year":"2024","unstructured":"Chaji D, Malloy L, Meredyth D, et al. Implementing Australia\u2019s first national cancer control plan to shape Australian cancer control policy for the next decade and beyond. Holistic Integr Oncol. 2024;3(1):40.","journal-title":"Holistic Integr Oncol."},{"key":"949_CR9","unstructured":"NHS England. Accelerating genomic medicine in the NHS, a strategy for embedding genomics in the NHS over the next 5 years 2022 [updated 12\/10\/22]. Available from: https:\/\/www.england.nhs.uk\/long-read\/accelerating-genomic-medicine-in-the-nhs\/#:~:text=Over%20the%20next%203%20%E2%80%93%205,of%20BRCA%20testing%20in%20higher. Accessed 30 Jan 2025."},{"key":"949_CR10","volume-title":"Accelerating access to genomics for global health: promotion, implementation, collaboration, and ethical, legal, and social issues","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Accelerating access to genomics for global health: promotion, implementation, collaboration, and ethical, legal, and social issues. A report of the WHO Science Council. Geneva: World Health Organization; 2022."},{"issue":"1","key":"949_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.20892\/j.issn.2095-3941.2023.0420","volume":"21","author":"Y Katsuya","year":"2024","unstructured":"Katsuya Y. Current and future trends in whole genome sequencing in cancer. Cancer Biol Med. 2024;21(1):16\u201320.","journal-title":"Cancer Biol Med"},{"issue":"3","key":"949_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41431-022-01259-8","volume":"31","author":"GA Alarc\u00f3n Garavito","year":"2023","unstructured":"Alarc\u00f3n Garavito GA, Moniz T, Redin F, et al. The implementation of large-scale genomic screening or diagnostic programmes: a rapid evidence review. Eur J Hum Genet. 2023;31(3):282\u201395.","journal-title":"Eur J Hum Genet"},{"issue":"7","key":"949_CR13","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41436-018-0378-9","volume":"21","author":"AM Zebrowski","year":"2019","unstructured":"Zebrowski AM, Ellis DE, Barg FK, et al. Qualitative study of system-level factors related to genomic implementation. Genet Med. 2019;21(7):1534\u201340.","journal-title":"Genet Med"},{"issue":"1","key":"949_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3892\/mco.2021.2453","volume":"16","author":"K Christofyllakis","year":"2022","unstructured":"Christofyllakis K, Bittenbring JT, Thurner L, et al. Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (review). Mol Clin Oncol. 2022;16(1):21.","journal-title":"Mol Clin Oncol."},{"issue":"5","key":"949_CR15","volume":"2","author":"DA Marshall","year":"2024","unstructured":"Marshall DA, Hua N, Buchanan J, et al. Paving the path for implementation of clinical genomic sequencing globally: are we ready? Health Aff Sch. 2024;2(5):qxae053.","journal-title":"Health Aff Sch."},{"issue":"3","key":"949_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ajhg.2023.01.018","volume":"110","author":"Z Stark","year":"2023","unstructured":"Stark Z, Boughtwood T, Haas M, et al. Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare. Am J Hum Genet. 2023;110(3):419\u201326.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"949_CR17","doi-asserted-by":"publisher","first-page":"9660","DOI":"10.3390\/curroncol30110700","volume":"30","author":"D Husereau","year":"2023","unstructured":"Husereau D, Bombard Y, Stockley T, et al. Future role of health technology asessment for genomic medicine in oncology: a Canadian laboratory perspective. Curr Oncol. 2023;30(11):9660\u20139.","journal-title":"Curr Oncol"},{"issue":"9","key":"949_CR18","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jval.2024.04.023","volume":"27","author":"M Mirza","year":"2024","unstructured":"Mirza M, Goerke L, Anderson A, et al. Assessing the cost-effectiveness of next-generation sequencing as a biomarker testing approach in oncology and policy implications: a literature review. Value Health. 2024;27(9):1300\u20139.","journal-title":"Value Health."},{"issue":"2","key":"949_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.gim.2021.10.008","volume":"24","author":"K Johnson","year":"2022","unstructured":"Johnson K, Saylor KW, Guynn I, et al. A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders. Genet Med. 2022;24(2):262\u201388.","journal-title":"Genet Med"},{"issue":"1","key":"949_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13696998.2022.2152233","volume":"26","author":"S Teppala","year":"2023","unstructured":"Teppala S, Hodgkinson B, Hayes S, et al. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. J Med Econ. 2023;26(1):19\u201333.","journal-title":"J Med Econ"},{"key":"949_CR21","unstructured":"McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.5. Cochrane; 2024. Available from www.training.cochrane.org\/handbook."},{"issue":"10","key":"949_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/gim.2017.247","volume":"20","author":"K Schwarze","year":"2018","unstructured":"Schwarze K, Buchanan J, Taylor JC, et al. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20(10):1122\u201330.","journal-title":"Genet Med"},{"issue":"6","key":"949_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100829","volume":"25","author":"F Santos Gonzalez","year":"2023","unstructured":"Santos Gonzalez F, Mordaunt D, Stark Z, et al. Microcosting diagnostic genomic sequencing: a systematic review. Genet Med. 2023;25(6): 100829.","journal-title":"Genet Med"},{"issue":"6","key":"949_CR24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/ejhg.2017.10","volume":"25","author":"JN Kohler","year":"2017","unstructured":"Kohler JN, Turbitt E, Biesecker BB, et al. Personal utility in genomic testing: a systematic literature review. Eur J Hum Genet. 2017;25(6):662\u20138.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"949_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40273-019-00856-8","volume":"38","author":"P Fahr","year":"2020","unstructured":"Fahr P, Buchanan J, Wordsworth S. A review of health economic studies comparing traditional and massively parallel sequencing diagnostic pathways for suspected genetic disorders. Pharmacoeconomics. 2020;38(2):143\u201358.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"949_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25980","volume":"5","author":"KP Callahan","year":"2022","unstructured":"Callahan KP, Mueller R, Flibotte J, et al. Measures of utility among studies of genomic medicine for critically ill infants: a systematic review. JAMA Netw Open. 2022;5(8): e2225980.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"949_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.10367","volume":"6","author":"EG Miller","year":"2023","unstructured":"Miller EG, Young JL, Rao A, et al. Demographic characteristics associated with perceptions of personal utility in genetic and genomic testing: a systematic review. JAMA Netw Open. 2023;6(5): e2310367.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"949_CR28","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1001\/jamaoncol.2020.1460","volume":"6","author":"G Mohan","year":"2020","unstructured":"Mohan G, Chattopadhyay S. Cost-effectiveness of leveraging social determinants of health to improve breast, cervical, and colorectal cancer screening: a systematic review. JAMA Oncol. 2020;6(9):1434\u201344.","journal-title":"JAMA Oncol"},{"issue":"2","key":"949_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55388","volume":"6","author":"AN Ehsan","year":"2023","unstructured":"Ehsan AN, Wu CA, Minasian A, et al. Financial toxicity among patients with breast cancer worldwide: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(2): e2255388.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"949_CR30","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaac.2020.05.009","volume":"59","author":"ME Loades","year":"2020","unstructured":"Loades ME, Chatburn E, Higson-Sweeney N, et al. Rapid systematic review: the impact of social isolation and loneliness on the mental health of children and adolescents in the context of COVID-19. J Am Acad Child Adolesc Psychiatry. 2020;59(11):1218-39.e3.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"949_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160.","journal-title":"BMJ"},{"key":"949_CR32","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"key":"949_CR33","unstructured":"XE. Historical rate tables 2024. Available from: https:\/\/www.xe.com\/currencytables\/. Accessed 30 Jan 2025."},{"issue":"1","key":"949_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12913-021-06396-2","volume":"21","author":"JZY Wong","year":"2021","unstructured":"Wong JZY, Chai JH, Yeoh YS, et al. Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore. BMC Health Serv Res. 2021;21(1):379.","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"949_CR35","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2018.1901","volume":"4","author":"N Pashayan","year":"2018","unstructured":"Pashayan N, Morris S, Gilbert FJ, et al. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. JAMA Oncol. 2018;4(11):1504\u201310.","journal-title":"JAMA Oncol"},{"issue":"10","key":"949_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.22874","volume":"3","author":"GF Guzauskas","year":"2020","unstructured":"Guzauskas GF, Garbett S, Zhou Z, et al. Cost-effectiveness of population-wide genomic screening for hereditary breast and ovarian cancer in the United States. JAMA Netw Open. 2020;3(10): e2022874.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"949_CR37","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10198-019-01038-1","volume":"20","author":"D Muller","year":"2019","unstructured":"Muller D, Danner M, Schmutzler R, et al. Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer. Eur J Health Econ. 2019;20(5):739\u201350.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"949_CR38","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1158\/1940-6207.CAPR-20-0411","volume":"14","author":"N Michaan","year":"2021","unstructured":"Michaan N, Leshno M, Safra T, et al. Cost effectiveness of whole population BRCA genetic screening for cancer prevention in Israel. Cancer Prev Res. 2021;14(4):455\u201362.","journal-title":"Cancer Prev Res"},{"issue":"3","key":"949_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/14737167.2023.2169135","volume":"23","author":"M Oh","year":"2023","unstructured":"Oh M, McBride A, Bhattacharjee S, et al. The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Rev Pharmacoecon Outcomes Res. 2023;23(3):309\u201316.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"949_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12071929","volume":"12","author":"R Manchanda","year":"2020","unstructured":"Manchanda R, Sun L, Patel S, et al. Economic evaluation of population-based brca1\/brca2 mutation testing across multiple countries and health systems. Cancers. 2020;12(7):1\u201338.","journal-title":"Cancers"},{"issue":"24","key":"949_CR41","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.3390\/cancers14246113","volume":"14","author":"R Michaelson-Cohen","year":"2022","unstructured":"Michaelson-Cohen R, Cohen MJ, Cohen C, et al. Real world cost-effectiveness analysis of population screening for BRCA variants among Ashkenazi Jews compared with family history-based strategies. Cancers. 2022;14(24):6113.","journal-title":"Cancers"},{"issue":"7","key":"949_CR42","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/jnci\/djx265","volume":"110","author":"R Manchanda","year":"2018","unstructured":"Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Instit. 2018;110(7):714\u201325.","journal-title":"J Natl Cancer Instit."},{"issue":"1","key":"949_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40258-020-00599-0","volume":"19","author":"J Simoes Correa-Galendi","year":"2021","unstructured":"Simoes Correa-Galendi J, Del Pilar Eztevez Diz M, Stock S, et al. Economic modelling of screen-and-treat strategies for Brazilian women at risk of hereditary breast and ovarian cancer. Appl Health Econ Health Policy. 2021;19(1):97\u2013109.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"949_CR44","doi-asserted-by":"publisher","first-page":"431.e1","DOI":"10.1016\/j.ajog.2017.12.221","volume":"218","author":"S Patel","year":"2018","unstructured":"Patel S, Legood R, Evans DG, et al. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. Am J Obstet Gynecol. 2018;218(4):431.e1-12.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"949_CR45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12885-022-09613-1","volume":"22","author":"S Mital","year":"2022","unstructured":"Mital S, Nguyen HV. Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening. BMC Cancer. 2022;22(1):501.","journal-title":"BMC Cancer"},{"issue":"1","key":"949_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ygyno.2019.01.018","volume":"153","author":"P Hoskins","year":"2019","unstructured":"Hoskins P, Eccleston A, Hurry M, et al. Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer: a Canadian model. Gynecol Oncol. 2019;153(1):87\u201391.","journal-title":"Gynecol Oncol"},{"key":"949_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.11606\/S1518-8787.2018052000643","volume":"52","author":"MCdA Ramos","year":"2018","unstructured":"Ramos MCdA, Folgueira MAAK, Maistro S, et al. Cost effectiveness of the cancer prevention program for carriers of the BRCA1\/2 mutation. Rev Saude Publica. 2018;52:94.","journal-title":"Rev Saude Publica"},{"issue":"8","key":"949_CR48","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s12094-018-02026-2","volume":"21","author":"C Moya-Alarcon","year":"2019","unstructured":"Moya-Alarcon C, Gonzalez-Dominguez A, Simon S, et al. Cost-utility analysis of germline BRCA1\/2 testing in women with high-grade epithelial ovarian cancer in Spain. Clin Trans Oncol. 2019;21(8):1076\u201384.","journal-title":"Clin Trans Oncol"},{"issue":"3","key":"949_CR49","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ygyno.2018.10.014","volume":"152","author":"JS Kwon","year":"2019","unstructured":"Kwon JS, Tinker AV, Hanley GE, et al. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer. Gynecol Oncol. 2019;152(3):459\u201364.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"949_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1017\/S0266462319003519","volume":"36","author":"M Hurry","year":"2020","unstructured":"Hurry M, Eccleston A, Dyer M, et al. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast\/ovarian cancers compared to treatment if cancer develops. Int J Techol Assess Health Care. 2020;36(2):104\u201312.","journal-title":"Int J Techol Assess Health Care."},{"issue":"7","key":"949_CR51","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/cancers14071839","volume":"14","author":"L Sun","year":"2022","unstructured":"Sun L, Cui B, Wei X, et al. Cost-effectiveness of genetic testing for all women diagnosed with breast cancer in China. Cancers. 2022;14(7):1839.","journal-title":"Cancers"},{"issue":"9","key":"949_CR52","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/gim.2017.231","volume":"20","author":"HW Tuffaha","year":"2018","unstructured":"Tuffaha HW, Mitchell A, Ward RL, et al. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. Genet Med. 2018;20(9):985\u201394.","journal-title":"Genet Med"},{"key":"949_CR53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3389\/fonc.2022.951310","volume":"12","author":"M Lourencao","year":"2022","unstructured":"Lourencao M, Simoes Correa Galendi J, Galvao HDCR, et al. Cost-effectiveness of BRCA 1\/2 genetic test and preventive strategies: using real-world data from an upper-middle income country. Front Oncol. 2022;12:811\u201322.","journal-title":"Front Oncol"},{"issue":"5","key":"949_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4428","volume":"2","author":"Z Kemp","year":"2019","unstructured":"Kemp Z, Turnbull A, Yost S, et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Netw Open. 2019;2(5): e194428.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"949_CR55","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1158\/1940-6207.CAPR-20-0620","volume":"14","author":"C Thomas","year":"2021","unstructured":"Thomas C, Mandrik O, Saunders CL, et al. The costs and benefits of risk stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis. Cancer Prev Res. 2021;14(8):811\u201322.","journal-title":"Cancer Prev Res"},{"issue":"1","key":"949_CR56","first-page":"10","volume":"29","author":"DR Cenin","year":"2020","unstructured":"Cenin DR, Naber SK, de Weerdt AC, et al. Cost-effectiveness of personalized screening for colorectal cancer based on polygenic risk and family history. Cancer Epidemiol. 2020;29(1):10\u201321.","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"949_CR57","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/1055-9965.EPI-19-1580","volume":"30","author":"E Biltaji","year":"2021","unstructured":"Biltaji E, Walker B, Au TH, et al. Can cost-effectiveness analysis inform genotype-guided aspirin use for primary colorectal cancer prevention? Cancer Epidemiol Biomarkers Prev. 2021;30(6):1106\u201313.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"13","key":"949_CR58","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1016\/j.cgh.2023.03.003","volume":"21","author":"R van den Puttelaar","year":"2023","unstructured":"van den Puttelaar R, Meester RGS, Peterse EFP, et al. Risk-stratified screening for colorectal cancer using genetic and environmental risk factors: a cost-effectiveness analysis based on real-world data. Clin Gastroenterol Hepatol. 2023;21(13):3415-23.e29.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"16","key":"949_CR59","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/ijerph18168330","volume":"18","author":"AR Ramdzan","year":"2021","unstructured":"Ramdzan AR, Manaf MRA, Aizuddin AN, et al. Cost-Effectiveness of colorectal cancer genetic testing. Int J Environ Res Public Health. 2021;18(16):1106\u201313.","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"949_CR60","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.dld.2019.07.012","volume":"51","author":"C Pereira","year":"2019","unstructured":"Pereira C, Areia M, Dinis-Ribeiro M. Cost-utility analysis of genetic polymorphism universal screening in colorectal cancer prevention by detection of high-risk individuals. Digest Liver Dis. 2019;51(12):1731\u20137.","journal-title":"Digest Liver Dis."},{"issue":"1","key":"949_CR61","doi-asserted-by":"publisher","first-page":"pkz086","DOI":"10.1093\/jncics\/pkz086","volume":"4","author":"SK Naber","year":"2020","unstructured":"Naber SK, Kundu S, Kuntz KM, et al. Cost-effectiveness of risk-stratified colorectal cancer screening based on polygenic risk: current status and future potential. JNCI Cancer Spectr. 2020;4(1):pkz086.","journal-title":"JNCI Cancer Spectr."},{"issue":"2","key":"949_CR62","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5694\/mja2.50356","volume":"212","author":"Y-J Kang","year":"2020","unstructured":"Kang Y-J, Killen J, Caruana M, et al. The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome. Med J Aust. 2020;212(2):72\u201381.","journal-title":"Med J Aust"},{"issue":"7","key":"949_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235038","volume":"15","author":"R Pastorino","year":"2020","unstructured":"Pastorino R, Basile M, Tognetto A, et al. Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy. PLoS ONE. 2020;15(7): e0235038.","journal-title":"PLoS ONE"},{"issue":"4","key":"949_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5812\/ijcm.108198","volume":"14","author":"H Azardoost","year":"2021","unstructured":"Azardoost H, Rahimi F, Zeinalian M, et al. Cost-effectiveness analysis of molecular screening to identify Lynch syndrome in the patients with colorectal cancer. Int J Cancer Manage. 2021;14(4):1\u20137.","journal-title":"Int J Cancer Manage."},{"issue":"8","key":"949_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221419","volume":"14","author":"TM Snowsill","year":"2019","unstructured":"Snowsill TM, Ryan NAJ, Crosbie EJ, et al. Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting. PLoS ONE. 2019;14(8): e0221419.","journal-title":"PLoS ONE"},{"issue":"6","key":"949_CR66","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/jcm9061664","volume":"9","author":"TM Snowsill","year":"2020","unstructured":"Snowsill TM, Ryan NAJ,\u00a0Crosbie EJ. Cost-effectiveness of the manchester approach to identifying lynch syndrome in women with endometrial cancer. J Clin Med. 2020;9(6):1664.","journal-title":"J Clin Med"},{"issue":"42","key":"949_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta25420","volume":"25","author":"C Stinton","year":"2021","unstructured":"Stinton C, Jordan M, Fraser H, et al. Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation. Health Technol Assess. 2021;25(42):1\u2013216.","journal-title":"Health Technol Assess"},{"issue":"9","key":"949_CR68","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/jmedgenet-2021-108062","volume":"59","author":"I Salikhanov","year":"2022","unstructured":"Salikhanov I, Heinimann K, Chappuis P, et al. Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives. J Med Genet. 2022;59(9):924\u201330.","journal-title":"J Med Genet"},{"issue":"2","key":"949_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246674","volume":"16","author":"AA Karlsson","year":"2021","unstructured":"Karlsson AA, Hao S, Jauhiainen A, et al. The cost-effectiveness of prostate cancer screening using the Stockholm3 test. PLoS ONE. 2021;16(2): e0246674.","journal-title":"PLoS ONE"},{"issue":"1","key":"949_CR70","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.eururo.2021.12.021","volume":"82","author":"S Hao","year":"2022","unstructured":"Hao S, Heintz E, \u00d6stensson E, et al. Cost-effectiveness of the Stockholm3 Test and magnetic resonance imaging in prostate cancer screening: a microsimulation study. Eur Urol. 2022;82(1):12\u20139.","journal-title":"Eur Urol"},{"issue":"12","key":"949_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002998","volume":"16","author":"T Callender","year":"2019","unstructured":"Callender T, Emberton M, Morris S, et al. Polygenic risk-tailored screening for prostate cancer: a benefit\u2013harm and cost-effectiveness modelling study. PLoS Med. 2019;16(12): e1002998.","journal-title":"PLoS Med"},{"issue":"10","key":"949_CR72","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1093\/aje\/kwab155","volume":"190","author":"N Hendrix","year":"2021","unstructured":"Hendrix N, Gulati R, Jiao B, et al. Clarifying the trade-offs of risk-stratified screening for prostate cancer: a cost-effectiveness study. Am J Epidemiol. 2021;190(10):2064\u201374.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"949_CR73","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40273-022-01181-3","volume":"40","author":"A Tafazzoli","year":"2022","unstructured":"Tafazzoli A, Ramsey SD, Shaul A, et al. The potential value-based price of a multi-cancer early detection genomic blood test to complement current single cancer screening in the USA. Pharmacoeconomics. 2022;40(11):1107\u201317.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"949_CR74","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41416-021-01498-4","volume":"125","author":"A Hackshaw","year":"2021","unstructured":"Hackshaw A, Cohen SS, Reichert H, et al. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Br J Cancer. 2021;125(10):1432\u201342.","journal-title":"Br J Cancer"},{"issue":"1","key":"949_CR75","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13073-023-01223-1","volume":"15","author":"AL Davidson","year":"2023","unstructured":"Davidson AL, Dressel U, Norris S, et al. The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants-a multi-site prospective cohort study. Genome Med. 2023;15(1):74.","journal-title":"Genome Med."},{"key":"949_CR76","doi-asserted-by":"publisher","first-page":"102297","DOI":"10.1016\/j.eclinm.2023.102297","volume":"66","author":"P Lacaze","year":"2023","unstructured":"Lacaze P, Marquina C, Tiller J, et al. Combined population genomic screening for three high-risk conditions in Australia: a modelling study. eClinicalMedicine. 2023;66:102297.","journal-title":"eClinicalMedicine."},{"issue":"7","key":"949_CR77","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s41436-021-01124-x","volume":"23","author":"JM Yeh","year":"2021","unstructured":"Yeh JM, Stout NK, Chaudhry A, et al. Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. Genet Med. 2021;23(7):1366\u201371.","journal-title":"Genet Med"},{"issue":"3","key":"949_CR78","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40258-018-0384-8","volume":"16","author":"KK Lim","year":"2018","unstructured":"Lim KK, Yoon SY, Mohd Taib NA, et al. Is BRCA mutation testing cost effective for early stage breast cancer patients compared to routine clinical surveillance? The case of an upper middleiIncome country in Asia. Appl Health Econ Health Policy. 2018;16(3):395\u2013406.","journal-title":"Appl Health Econ Health Policy"},{"issue":"12","key":"949_CR79","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3390\/jpm11121284","volume":"11","author":"J Hao","year":"2021","unstructured":"Hao J, Hassen D, Gudgeon JM, et al. Economic evaluation of universal lynch syndrome screening protocols among newly diagnosed patients with colorectal cancer. J Pers Med. 2021;11(12):1284.","journal-title":"J Pers Med."},{"issue":"1","key":"949_CR80","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.surg.2017.10.004","volume":"163","author":"CJ Balentine","year":"2018","unstructured":"Balentine CJ, Vanness DJ,\u00a0Schneider DF. Cost-effectiveness of lobectomy versus genetic testing (Afirma\u00ae) for indeterminate thyroid nodules: considering the costs of surveillance. Surgery. 2018;163(1):88\u201396.","journal-title":"Surgery"},{"issue":"9","key":"949_CR81","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamadermatol.2018.1764","volume":"154","author":"J Hornberger","year":"2018","unstructured":"Hornberger J, Siegel DM. Economic analysis of a noninvasive molecular pathologic assay for pigmented skin lesions. JAMA Dermatol. 2018;154(9):1025\u201331.","journal-title":"JAMA Dermatol"},{"key":"949_CR82","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/BCTT.S387375","volume":"15","author":"EM Jongbloed","year":"2023","unstructured":"Jongbloed EM, Blommestein HM, van Schoubroeck HM, et al. Cost-effectiveness of abemaciclib in early breast cancer patients: one size fits all or tailoring to patients\u2019 needs? Breast Cancer Targets Ther. 2023;15:147\u201361.","journal-title":"Breast Cancer Targets Ther."},{"issue":"5","key":"949_CR83","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s12094-019-02176-x","volume":"22","author":"S Perez Ramirez","year":"2020","unstructured":"Perez Ramirez S, Del Monte-Millan M, Lopez-Tarruella S, et al. Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience. Clin Transl Oncol. 2020;22(5):717\u201324.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"949_CR84","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12962-023-00449-5","volume":"21","author":"L Rojas","year":"2023","unstructured":"Rojas L, Rojas-Reyes MX, Rosselli D, et al. Cost-utility analysis of genomic profiling in early breast cancer in Colombia. Cost Effect Resour Alloc. 2023;21(1):42.","journal-title":"Cost Effect Resour Alloc."},{"key":"949_CR85","doi-asserted-by":"publisher","first-page":"1191943","DOI":"10.3389\/fonc.2023.1191943","volume":"13","author":"E Curtit","year":"2023","unstructured":"Curtit E, Bellanger MM, Nerich V, et al. Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis. Front Oncol. 2023;13:1191943.","journal-title":"Front Oncol"},{"issue":"3","key":"949_CR86","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s12325-022-02047-y","volume":"39","author":"JA Sussell","year":"2022","unstructured":"Sussell JA, Roth JA, Meyer CS, et al. Assessment of the cost-effectiveness of HER2-targeted treatment pathways in the neoadjuvant treatment of high-risk HER2-positive early-stage breast cancer. Adv Ther. 2022;39(3):1375\u201392.","journal-title":"Adv Ther"},{"issue":"1","key":"949_CR87","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.gaceta.2018.07.012","volume":"34","author":"O Ibarrondo","year":"2020","unstructured":"Ibarrondo O, Alvarez-Lopez I, Freundlich F, et al. Probabilistic cost-utility analysis and expected value of perfect information for the oncotype multigenic test: a discrete event simulation model. Gac Sanit. 2020;34(1):61\u20138.","journal-title":"Gac Sanit"},{"issue":"3","key":"949_CR88","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5152\/ejbh.2019.4761","volume":"15","author":"V Ozmen","year":"2019","unstructured":"Ozmen V, Cakar B, Gokmen E, et al. Cost effectiveness of gene expression profiling in patients with early-stage breast cancer in a middleincome country, Turkey: results of a prospective multicenter study. Eur J Breast Health. 2019;15(3):183\u201390.","journal-title":"Eur J Breast Health."},{"issue":"1","key":"949_CR89","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2217\/pgs-2019-0073","volume":"21","author":"X Wei","year":"2020","unstructured":"Wei X, Cai J, Zhuang J, et al. CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer. Pharmacogenomics. 2020;21(1):43\u201353.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"949_CR90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40261-019-00842-0","volume":"40","author":"X Wei","year":"2020","unstructured":"Wei X, Sun H, Zhuang J, et al. Cost-effectiveness analysis of CYP2D6*10 pharmacogenetic testing to guide the adjuvant endocrine therapy for postmenopausal women with estrogen receptor positive early breast cancer in China. Clin Drug Invest. 2020;40(1):25\u201332.","journal-title":"Clin Drug Invest"},{"issue":"1","key":"949_CR91","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-017-4582-0","volume":"168","author":"A Trentham-Dietz","year":"2018","unstructured":"Trentham-Dietz A, Ergun MA, Alagoz O, et al. Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening. Breast Cancer Res Treat. 2018;168(1):229\u201339.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"949_CR92","doi-asserted-by":"publisher","first-page":"39","DOI":"10.6004\/jnccn.2018.7077","volume":"17","author":"S-Y Wang","year":"2019","unstructured":"Wang S-Y, Chen T, Dang W, et al. Incorporating tumor characteristics to maximize 21-gene assay utility: a cost-effectiveness analysis. J Natl Compr Cancer Network. 2019;17(1):39\u201346.","journal-title":"J Natl Compr Cancer Network."},{"key":"949_CR93","doi-asserted-by":"publisher","first-page":"5909724","DOI":"10.1155\/2022\/5909724","volume":"2022","author":"FE De Jongh","year":"2022","unstructured":"De Jongh FE, Efe R, Herrmann KH, et al. Cost and clinical benefits associated with Oncotype DX\u00ae test in patients with early-stage HR+\/HER2-node-negative breast cancer in the Netherlands. Int J Breast Cancer. 2022;2022:5909724.","journal-title":"Int J Breast Cancer."},{"issue":"10","key":"949_CR94","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.jval.2022.04.001","volume":"25","author":"N Alrawashdh","year":"2022","unstructured":"Alrawashdh N, McBride A, Erstad B, et al. Cost-effectiveness and economic burden analyses on all first-line treatments of chronic lymphocytic leukemia. Value Health. 2022;25(10):1685\u201395.","journal-title":"Value Health."},{"issue":"2","key":"949_CR95","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s41669-022-00375-x","volume":"7","author":"A Chatterjee","year":"2023","unstructured":"Chatterjee A, van de Wetering G, Goeree R, et al. A probabilistic cost-effectiveness analysis of venetoclax and obinutuzumab as a first-line therapy in chronic lymphocytic leukemia in Canada. Pharmacoeconomics Open. 2023;7(2):199\u2013216.","journal-title":"Pharmacoeconomics Open."},{"issue":"15","key":"949_CR96","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1182\/bloodadvances.2023010108","volume":"7","author":"M Slot","year":"2023","unstructured":"Slot M, Niemann CU, Ehlers LH, et al. Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations. Blood Adv. 2023;7(15):4186\u201396.","journal-title":"Blood Adv"},{"issue":"5","key":"949_CR97","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14737167.2023.2196408","volume":"23","author":"T Munir","year":"2023","unstructured":"Munir T, Genovez V, Genestier V, et al. Cost-effectiveness of acalabrutinib regimens in treatment-naive chronic lymphocytic leukemia in the United States. Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):579\u201389.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"949_CR98","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12185-021-03237-0","volume":"115","author":"X Wei","year":"2022","unstructured":"Wei X, Zhuang J, Li N, et al. NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China. Int J Hematol. 2022;115(2):278\u201386.","journal-title":"Int J Hematol"},{"issue":"7","key":"949_CR99","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1080\/10428194.2017.1390230","volume":"59","author":"Q Chen","year":"2018","unstructured":"Chen Q, Staton AD, Ayer T, et al. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk lymphoma. 2018;59(7):1700\u20139.","journal-title":"Leuk lymphoma"},{"issue":"4","key":"949_CR100","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/cancers14040908","volume":"14","author":"DA Regier","year":"2022","unstructured":"Regier DA, Chan B, Costa S, et al. Cost-effectiveness of molecularly guided treatment in diffuse large B-cell lymphoma (DLBCL) in patients under 60. Cancers. 2022;14(4):908.","journal-title":"Cancers"},{"issue":"3","key":"949_CR101","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2217\/pgs-2017-0140","volume":"19","author":"JG Gaultney","year":"2018","unstructured":"Gaultney JG, Ng TW, Uyl-de Groot CA, et al. Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe. Pharmacogenomics. 2018;19(3):213\u201326.","journal-title":"Pharmacogenomics"},{"issue":"23","key":"949_CR102","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.21037\/atm-2022-77","volume":"10","author":"VS Chaudhari","year":"2022","unstructured":"Chaudhari VS, Issa AM. Cost-effectiveness of precision molecular diagnostic tests for stage II colorectal cancer. Ann Transl Med. 2022;10(23):1260.","journal-title":"Ann Transl Med."},{"key":"949_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106949","volume":"197","author":"V Fragoulakis","year":"2023","unstructured":"Fragoulakis V, Roncato R, Bignucolo A, et al. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study. Pharmacol Res. 2023;197: 106949.","journal-title":"Pharmacol Res"},{"issue":"4","key":"949_CR104","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40258-018-0395-5","volume":"16","author":"G Harty","year":"2018","unstructured":"Harty G, Jarrett J,\u00a0Jofre-Bonet M. Consequences of biomarker analysis on the cost-effectiveness of cetuximab in combination with FOLFIRI as a first-line treatment of metastatic colorectal cancer: personalised medicine at work. Appl Health Econ Health Policy. 2018;16(4):515\u201325.","journal-title":"Appl Health Econ Health Policy"},{"key":"949_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.651299","volume":"11","author":"SF Lee","year":"2021","unstructured":"Lee SF, Choi HCW, Chan SK, et al. Cost-effectiveness of anti-epidermal growth factor receptor therapy versus bevacizumab in KRAS wild-type (WT), Pan-RAS WT, and Pan-RAS WT left-sided metastatic colorectal cancer. Front Oncol. 2021;11: 651299.","journal-title":"Front Oncol"},{"issue":"3","key":"949_CR106","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.19963","volume":"3","author":"SR Jang","year":"2020","unstructured":"Jang SR, Truong H, Oh A, et al. Cost-effectiveness evaluation of targeted surgical and endoscopic therapies for early colorectal adenocarcinoma based on biomarker profiles. JAMA Netw Open. 2020;3(3): e1919963.","journal-title":"JAMA Netw Open"},{"key":"949_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630953","volume":"11","author":"AJ Kacew","year":"2021","unstructured":"Kacew AJ, Strohbehn GW, Saulsberry L, et al. Artificial intelligence can cut costs while maintaining accuracy in colorectal cancer genotyping. Front Oncol. 2021;11: 630953.","journal-title":"Front Oncol"},{"key":"949_CR108","doi-asserted-by":"publisher","first-page":"1103055","DOI":"10.3389\/fimmu.2022.1103055","volume":"13","author":"K Liu","year":"2022","unstructured":"Liu K, Zhu Y,\u00a0Zhu H. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Immunol. 2022;13:1103055.","journal-title":"Front Immunol"},{"issue":"3","key":"949_CR109","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.surg.2020.06.038","volume":"169","author":"AN Krepline","year":"2021","unstructured":"Krepline AN, Geurts JL, George B, et al. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Surgery. 2021;169(3):629\u201335.","journal-title":"Surgery"},{"issue":"3","key":"949_CR110","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ygyno.2022.06.015","volume":"166","author":"K Liu","year":"2022","unstructured":"Liu K, Zhu Y, Zhou Y, et al. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: a United States-based cost-effectiveness analysis. Gynecol Oncol. 2022;166(3):582\u20138.","journal-title":"Gynecol Oncol"},{"key":"949_CR111","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ygyno.2023.04.010","volume":"173","author":"TJ Orellana","year":"2023","unstructured":"Orellana TJ, Kim H, Beriwal S, et al. Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer. Gynecol Oncol. 2023;173:81\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"949_CR112","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12887-021-03069-1","volume":"22","author":"JD Rios","year":"2022","unstructured":"Rios JD, Velummailum R, Bennett J, et al. Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma. BMC Pediatr. 2022;22(1):13.","journal-title":"BMC Pediatr"},{"issue":"1","key":"949_CR113","first-page":"vdad055","volume":"5","author":"T Ranjan","year":"2023","unstructured":"Ranjan T, Yu A, Elhamdani S, et al. Treatment of unmethylated MGMT-promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients\u2019 healthcare costs. Neurooncol Adv. 2023;5(1):vdad055.","journal-title":"Neurooncol Adv."},{"issue":"3","key":"949_CR114","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/cancers15030786","volume":"15","author":"I Tessler","year":"2023","unstructured":"Tessler I, Leshno M, Feinmesser G, et al. Is there a role for molecular testing for low-risk differentiated thyroid cancer? A cost-effectiveness analysis. Cancers. 2023;15(3):786.","journal-title":"Cancers"},{"issue":"2","key":"949_CR115","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jval.2022.08.006","volume":"26","author":"S Huygens","year":"2023","unstructured":"Huygens S, Vellekoop H, Versteegh M, et al. Cost-effectiveness analysis of treating patients with NTRK-positive cancer with the histology-independent therapy entrectinib. Value Health. 2023;26(2):193\u2013203.","journal-title":"Value Health"},{"issue":"6","key":"949_CR116","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.ajhg.2019.04.017","volume":"104","author":"V Fragoulakis","year":"2019","unstructured":"Fragoulakis V, Roncato R, Fratte CD, et al. Estimating the effectiveness of DPYD genotyping in Italian individuals suffering from cancer based on the cost of chemotherapy-induced toxicity. Am J Hum Genet. 2019;104(6):1158\u201368.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"949_CR117","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12687-021-00557-w","volume":"13","author":"D Weymann","year":"2022","unstructured":"Weymann D, Laskin J, Jones SJM, et al. Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care. J Community Genet. 2022;13(5):523\u20138.","journal-title":"J Community Genet"},{"issue":"1","key":"949_CR118","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s12885-021-08407-1","volume":"21","author":"E Nadal","year":"2021","unstructured":"Nadal E, Bautista D, Cabezon-Gutierrez L, et al. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario. BMC Cancer. 2021;21(1):689.","journal-title":"BMC Cancer"},{"key":"949_CR119","first-page":"82","volume":"9","author":"M Majem","year":"2022","unstructured":"Majem M, Alvarez R, Ortega AL, et al. Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain. Glob Reg Health Technol Assess. 2022;9:82\u201390.","journal-title":"Glob Reg Health Technol Assess."},{"issue":"3","key":"949_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247860","volume":"16","author":"JHS You","year":"2021","unstructured":"You JHS, Cho WCS, Ming WK, et al. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong: a cost-effectiveness analysis. PLoS ONE. 2021;16(3): e0247860.","journal-title":"PLoS ONE"},{"issue":"1","key":"949_CR121","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12885-022-09397-4","volume":"22","author":"F Rojo","year":"2022","unstructured":"Rojo F, Conde E, Torres H, et al. Clinical and economic impact of \u201cROS1-testing\u201d strategy compared to a \u201cno-ROS1-testing\u201d strategy in advanced NSCLC in Spain. BMC Cancer. 2022;22(1):292.","journal-title":"BMC Cancer"},{"issue":"10","key":"949_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205827","volume":"13","author":"S Lu","year":"2018","unstructured":"Lu S, Yu Y, Fu S, et al. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. PLoS ONE. 2018;13(10): e0205827.","journal-title":"PLoS ONE"},{"issue":"6","key":"949_CR123","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1590\/1516-3180.2018.0256170919","volume":"137","author":"P Aguiar Junior","year":"2019","unstructured":"Aguiar Junior P, Barreto CMN, Roitberg F, et al. Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: budget impact and strategies to improve access. A pharmacoeconomic study. Sao Paulo Med J. 2019;137(6):505\u201311.","journal-title":"Sao Paulo Med J"},{"key":"949_CR124","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00201","volume":"6","author":"HB Wolff","year":"2022","unstructured":"Wolff HB, Steeghs EMP, Mfumbilwa ZA, et al. Cost-effectiveness of parallel versus sequential testing of genetic aberrations for stage IV non-small-cell lung cancer in the Netherlands. JCO Precis Oncol. 2022;6: e2200201.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"949_CR125","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/14737167.2022.2078310","volume":"22","author":"E de Alava","year":"2022","unstructured":"de Alava E, Pareja MJ, Carcedo D, et al. Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective. Expert Rev Pharmacoecon Outcomes Res. 2022;22(6):1033\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"949_CR126","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00546","volume":"7","author":"E Arriola","year":"2023","unstructured":"Arriola E, Bernabe R, Campelo RG, et al. Cost-effectiveness of next-generation sequencing versus single-gene testing for the molecular diagnosis of patients with metastatic non-small-cell lung cancer from the perspective of Spanish reference centers. JCO Precis Oncol. 2023;7: e2200546.","journal-title":"JCO Precis Oncol"},{"issue":"101708809","key":"949_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.19.00002","volume":"3","author":"L Steuten","year":"2019","unstructured":"Steuten L, Goulart B, Meropol NJ, et al. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. JCO Clin Cancer Inform. 2019;3(101708809):1\u201310.","journal-title":"JCO Clin Cancer Inform."},{"key":"949_CR128","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/PO.20.00540","volume":"5","author":"MJ Harvey","year":"2021","unstructured":"Harvey MJ, Cunningham R, Sawchyn B, et al. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small-cell lung cancer. JCO Precis Oncol. 2021;5:1611\u201324.","journal-title":"JCO Precis Oncol"},{"key":"949_CR129","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","volume":"139","author":"AC Tan","year":"2020","unstructured":"Tan AC, Lai GGY, Tan GS, et al. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer. 2020;139:207\u201315.","journal-title":"Lung Cancer"},{"issue":"8","key":"949_CR130","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","volume":"24","author":"D Zou","year":"2022","unstructured":"Zou D, Ye W, Hess LM, et al. Diagnostic value and cost-effectiveness of next-generation sequencing-based testing for treatment of patients with advanced\/metastatic non-squamous non-small-cell lung cancer in the United States. J Mol Diagn. 2022;24(8):901\u201314.","journal-title":"J Mol Diagn"},{"key":"949_CR131","doi-asserted-by":"publisher","first-page":"1119506","DOI":"10.3389\/fmed.2023.1119506","volume":"10","author":"T Hofmarcher","year":"2023","unstructured":"Hofmarcher T, Malmberg C, Lindgren P.\u00a0A global analysis of the value of precision medicine in oncology: the case of non-small cell lung cancer. Front Med. 2023;10:1119506.","journal-title":"Front Med"},{"issue":"3","key":"949_CR132","doi-asserted-by":"publisher","first-page":"1701467","DOI":"10.1183\/13993003.01467-2017","volume":"51","author":"S Loubiere","year":"2018","unstructured":"Loubiere S, Drezet A, Beau-Faller M, et al. Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. Eur Respir J. 2018;51(3):1701467.","journal-title":"Eur Respir J"},{"issue":"12","key":"949_CR133","first-page":"1429","volume":"39","author":"MJHG Simons","year":"2021","unstructured":"Simons MJHG, Retel VP, Ramaekers BLT, et al. Early cost effectiveness of whole-genome sequencing as a clinical diagnostic test for patients with inoperable stage IIIB. C\/IV non-squamous non-small-cell lung cancer Pharmacoeconomics. 2021;39(12):1429\u201342.","journal-title":"C\/IV non-squamous non-small-cell lung cancer. Pharmacoeconomics."},{"issue":"1","key":"949_CR134","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jval.2022.07.006","volume":"26","author":"MJHG Simons","year":"2023","unstructured":"Simons MJHG, Uyl-de Groot CA, Retel VP, et al. Cost-effectiveness and budget impact of future developments with whole-genome sequencing for patients with lung cancer. Value Health. 2023;26(1):71\u201380.","journal-title":"Value Health."},{"key":"949_CR135","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221112696","volume":"14","author":"DA Ezeife","year":"2022","unstructured":"Ezeife DA, Spackman E, Juergens RA, et al. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Ther Adv Med Oncol. 2022;14:17588359221112696.","journal-title":"Ther Adv Med Oncol."},{"issue":"4","key":"949_CR136","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00432-022-04034-w","volume":"149","author":"F Englmeier","year":"2023","unstructured":"Englmeier F, Bleckmann A, Bruckl W, et al. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. J Cancer Res Clin Oncol. 2023;149(4):1495\u2013511.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"949_CR137","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3343\/alm.2023.43.6.605","volume":"43","author":"SM Cho","year":"2023","unstructured":"Cho SM, Lee HS, Jeon S, et al. Cost-effectiveness analysis of three diagnostic strategies for the detection of EGFR mutation in advanced non-small cell lung cancer. Ann Lab Med. 2023;43(6):605\u201313.","journal-title":"Ann Lab Med"},{"issue":"1","key":"949_CR138","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1186\/s12885-020-07240-2","volume":"20","author":"L Schluckebier","year":"2020","unstructured":"Schluckebier L, Caetano R, Garay OU, et al. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020;20(1):875.","journal-title":"BMC Cancer"},{"issue":"4","key":"949_CR139","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jval.2021.09.017","volume":"25","author":"OM Dong","year":"2022","unstructured":"Dong OM, Poonnen PJ, Winski D, et al. Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma. Value Health. 2022;25(4):582\u201394.","journal-title":"Value Health."},{"issue":"7","key":"949_CR140","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2217\/fon-2021-0785","volume":"18","author":"JH Leung","year":"2022","unstructured":"Leung JH, Chang C-W, Chan AL, et al. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. Future Oncol. 2022;18(7):859\u201370.","journal-title":"Future Oncol"},{"issue":"6","key":"949_CR141","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2217\/pme-2018-0141","volume":"16","author":"S Saito","year":"2019","unstructured":"Saito S, Nakazawa K, Nagahashi M, et al. Cost-effectiveness of BRCA1\/2 mutation profiling to target olaparib use in patients with metastatic breast cancer. Pers Med. 2019;16(6):439\u201348.","journal-title":"Pers Med"},{"key":"949_CR142","doi-asserted-by":"publisher","first-page":"1221969","DOI":"10.3389\/fonc.2023.1221969","volume":"13","author":"L Ren","year":"2023","unstructured":"Ren L, Ren N, Zheng Y, et al. Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer. Front Oncol. 2023;13:1221969.","journal-title":"Front Oncol"},{"key":"949_CR143","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2147\/CMAR.S339549","volume":"14","author":"N Pennarun","year":"2022","unstructured":"Pennarun N, Chiu JY, Chang HC, et al. Cost-effectiveness analysis from a societal perspective of recurrenceiIndex for distant recurrence (RecurIndex) in women with hormone receptor-positive and HER2-negative early-stage breast cancer. Cancer Manage Res. 2022;14:761\u201373.","journal-title":"Cancer Manage Res."},{"issue":"12","key":"949_CR144","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40261-018-0705-6","volume":"38","author":"S Nazha","year":"2018","unstructured":"Nazha S, Tanguay S, Kapoor A, et al. Cost-utility of sunitinib versus pazopanib in metastatic renal cell carcinoma in Canada using real-world evidence. Clin Drug Invest. 2018;38(12):1155\u201365.","journal-title":"Clin Drug Invest"},{"issue":"3","key":"949_CR145","doi-asserted-by":"publisher","first-page":"417.e1","DOI":"10.1016\/j.clgc.2022.11.014","volume":"21","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Ding D, et al. First-line lenvatinib plus pembrolizumab or everolimus versus sunitinib for advanced renal cell carcinoma: a United States-based cost-effectiveness analysis. Clin Genitourin Cancer. 2023;21(3):417.e1-10.","journal-title":"Clin Genitourin Cancer"},{"key":"949_CR146","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221085212","volume":"14","author":"T Chen","year":"2022","unstructured":"Chen T, Chen J, Chen C, et al. Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma. Ther Adv Med Oncol. 2022;14:17588359221085212.","journal-title":"Ther Adv Med Oncol"},{"key":"949_CR147","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2147\/CMAR.S188849","volume":"11","author":"J Redig","year":"2019","unstructured":"Redig J, Dalen J, Harmenberg U, et al. Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis. Cancer Manage Res. 2019;11:1289\u201397.","journal-title":"Cancer Manage Res."},{"issue":"1","key":"949_CR148","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/13696998.2023.2242197","volume":"26","author":"C Chandler","year":"2023","unstructured":"Chandler C, Burnett H, Schaible K, et al. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan. J Med Econ. 2023;26(1):1009\u201318.","journal-title":"J Med Econ"},{"key":"949_CR149","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/CEOR.S159833","volume":"10","author":"J Meng","year":"2018","unstructured":"Meng J, Lister J, Vataire AL, et al. Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. Clinicoecon Outcomes Res. 2018;10:243\u201350.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"7","key":"949_CR150","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40261-020-00922-6","volume":"40","author":"AG Bensimon","year":"2020","unstructured":"Bensimon AG, Zhou Z-Y, Jenkins M, et al. An economic evaluation of pembrolizumab versus other adjuvant treatment strategies for resected high-risk stage III melanoma in the USA. Clin Drug Invest. 2020;40(7):629\u201343.","journal-title":"Clin Drug Invest"},{"issue":"11","key":"949_CR151","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1001\/jamadermatol.2020.2398","volume":"156","author":"B Wu","year":"2020","unstructured":"Wu B, Shi L. Frontline BRAF testing-guided treatment for advanced melanoma in the era of immunotherapies: a cost-utility analysis based on long-term survival data. JAMA Dermatol. 2020;156(11):1177\u201384.","journal-title":"JAMA Dermatol"},{"issue":"13","key":"949_CR152","doi-asserted-by":"publisher","first-page":"9039","DOI":"10.1245\/s10434-021-10288-4","volume":"28","author":"SA Mojtahed","year":"2021","unstructured":"Mojtahed SA, Boyer NR, Rao SA, et al. Cost-effectiveness analysis of adjuvant therapy for BRAF-mutant resected stage III melanoma in Medicare patients. Ann Surg Oncol. 2021;28(13):9039\u201347.","journal-title":"Ann Surg Oncol"},{"issue":"101592642","key":"949_CR153","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.vhri.2021.04.008","volume":"26","author":"Y Gil-Rojas","year":"2021","unstructured":"Gil-Rojas Y, Lasalvia P, Hernandez F, et al. Cost-effectiveness of the dabrafenib schedule in combination with trametinib compared with other targeted therapies, immunotherapy, and dacarbazine for the treatment of unresectable or metastatic melanoma with BRAFV600 mutation in Colombia. Value Health Reg Issues. 2021;26(101592642):182\u201390.","journal-title":"Value Health Reg Issues."},{"issue":"1","key":"949_CR154","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12913-023-09058-7","volume":"23","author":"SN Li","year":"2023","unstructured":"Li SN, Wan X, Peng LB, et al. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. BMC Health Serv Res. 2023;23(1):49.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"949_CR155","doi-asserted-by":"publisher","first-page":"9255","DOI":"10.3390\/curroncol29120725","volume":"29","author":"M Kandel","year":"2022","unstructured":"Kandel M, Bardet A, Dalle S, et al. Cost-effectiveness analysis of sequential treatment strategies for advanced melanoma in real life in France. Curr Oncol. 2022;29(12):9255\u201370.","journal-title":"Curr Oncol"},{"issue":"1","key":"949_CR156","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13561-021-00347-7","volume":"12","author":"S Wahler","year":"2022","unstructured":"Wahler S, Muller A, Fuchs S, et al. Adjuvant treatment of high-risk melanoma: cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors. Health Econ Rev. 2022;12(1):8.","journal-title":"Health Econ Rev."},{"issue":"4","key":"949_CR157","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2217\/imt-2018-0168","volume":"11","author":"A Tarhini","year":"2019","unstructured":"Tarhini A, McDermott D, Ambavane A, et al. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Immunotherapy. 2019;11(4):283\u201395.","journal-title":"Immunotherapy"},{"issue":"2","key":"949_CR158","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1684\/ejd.2023.4448","volume":"33","author":"C Charpentier","year":"2023","unstructured":"Charpentier C, Riche V-P, Nguyen J-M, et al. Analysis of cost-effectiveness of chemotherapeutic agents and new therapies for the management of unresectable and metastatic melanoma. Eur J Dermatol. 2023;33(2):81\u20136.","journal-title":"Eur J Dermatol"},{"issue":"6","key":"949_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100303","volume":"6","author":"EEAP Mulder","year":"2021","unstructured":"Mulder EEAP, Smit L, Grunhagen DJ, et al. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. ESMO Open. 2021;6(6): 100303.","journal-title":"ESMO Open."},{"issue":"1","key":"949_CR160","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12962-023-00473-5","volume":"21","author":"Z-R Chen","year":"2023","unstructured":"Chen Z-R, Chueh C-H, Chiang N-J, et al. Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan\u2019s National Health Insurance Administration. Cost Eff Resour Alloc. 2023;21(1):61.","journal-title":"Cost Eff Resour Alloc."},{"issue":"3","key":"949_CR161","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40273-022-01227-6","volume":"41","author":"C-H Chueh","year":"2023","unstructured":"Chueh C-H, Tsai Y-W, Chen Z-R,et al. Cost-effectiveness analysis of a new second-line treatment regimen for advanced intrahepatic cholangiocarcinoma: biomarker-driven targeted therapy of pemigatinib versus 5-FU chemotherapy. Pharmacoeconomics. 2023;41(3):307\u201319.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"949_CR162","first-page":"1469","volume":"27","author":"BJ Pandya","year":"2021","unstructured":"Pandya BJ, Qi CZ, Garnham A, et al. Cost-effectiveness of gilteritinib for relapsed\/refractory FLT3mut+ acute myeloid leukemia. J Manage Care Spec Pharm. 2021;27(10):1469\u201381.","journal-title":"J Manage Care Spec Pharm."},{"issue":"3","key":"949_CR163","doi-asserted-by":"publisher","first-page":"E126","DOI":"10.5489\/cuaj.7495","volume":"16","author":"A Parmar","year":"2021","unstructured":"Parmar A, Timilshina N, Emmenegger U, et al. A cost-utility analysis of apalutamide for metastatic castration-sensitive prostate cancer. Can Urol Assoc J. 2021;16(3):E126\u201331.","journal-title":"Can Urol Assoc J"},{"issue":"11","key":"949_CR164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277282","volume":"17","author":"MC Barbier","year":"2022","unstructured":"Barbier MC, Tomonaga Y, Menges D, et al. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer. PLoS ONE. 2022;17(11): e0277282.","journal-title":"PLoS ONE"},{"key":"949_CR165","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.610601","volume":"11","author":"D Su","year":"2020","unstructured":"Su D, Wu B,\u00a0Shi L. Cost-effectiveness of genomic test-directed olaparib for metastatic castration-resistant prostate cancer. Front Pharmacol. 2020;11: 610601.","journal-title":"Front Pharmacol"},{"issue":"9","key":"949_CR166","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13565","volume":"3","author":"S Banerjee","year":"2020","unstructured":"Banerjee S, Kumar A, Lopez N, et al. Cost-effectiveness analysis of genetic testing and tailored first-line therapy for patients with metastatic gastrointestinal stromal tumors. JAMA Netw Open. 2020;3(9): e2013565.","journal-title":"JAMA Netw Open"},{"key":"949_CR167","doi-asserted-by":"publisher","first-page":"107327482311827","DOI":"10.1177\/10732748231182795","volume":"30","author":"MT Richardson","year":"2023","unstructured":"Richardson MT, Attwood K, Smith G, et al. Sequential targeted therapy for advanced, metastatic, and recurrent cervical cancer: a cost-effectiveness analysis of the patient journey. Cancer Control. 2023;30:10732748231182796.","journal-title":"Cancer Control"},{"issue":"4","key":"949_CR168","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2217\/pme-2022-0070","volume":"20","author":"H Vellekoop","year":"2023","unstructured":"Vellekoop H, Huygens S, Versteegh M, et al. Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries. Pers Med. 2023;20(4):321\u201338.","journal-title":"Pers Med"},{"issue":"8","key":"949_CR169","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/0284186X.2022.2098053","volume":"61","author":"AH Ree","year":"2022","unstructured":"Ree AH, Maelandsmo GM, Flatmark K, et al. Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer: the MetAction precision medicine study. Acta Oncol. 2022;61(8):955\u201362.","journal-title":"Acta Oncol"},{"issue":"6","key":"949_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22060","volume":"22","author":"SJ Edwards","year":"2018","unstructured":"Edwards SJ, Wakefield V, Cain P, et al. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2018;22(6):1\u2013278.","journal-title":"Health Technol Assess"},{"issue":"7","key":"949_CR171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021704","volume":"6","author":"L Orton","year":"2011","unstructured":"Orton L, Lloyd-Williams F, Taylor-Robinson D, et al. The use of research evidence in public health decision making processes: systematic review. PLoS ONE. 2011;6(7): e21704.","journal-title":"PLoS ONE"},{"issue":"4","key":"949_CR172","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ajhg.2020.08.005","volume":"107","author":"GP Patrinos","year":"2020","unstructured":"Patrinos GP, Pasparakis E, Koiliari E, et al. Roadmap for establishing large-scale genomic medicine initiatives in low- and middle-income countries. Am J Hum Genet. 2020;107(4):589\u201395.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"949_CR173","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41431-021-01022-5","volume":"30","author":"S Best","year":"2022","unstructured":"Best S, Vidic N, An K, et al. A systematic review of geographical inequities for accessing clinical genomic and genetic services for non-cancer related rare disease. Eur J Hum Genet. 2022;30(6):645\u201352.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"949_CR174","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","volume":"177","author":"G Sirugo","year":"2019","unstructured":"Sirugo G, Williams SM,\u00a0Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177(1):26\u201331.","journal-title":"Cell"},{"issue":"10","key":"949_CR175","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.gim.2022.07.011","volume":"24","author":"B Venning","year":"2022","unstructured":"Venning B, Saya S, De Abreu Lourenco R, et al. Preferences for a polygenic test to estimate cancer risk in a general Australian population. Genet Med. 2022;24(10):2144\u201354.","journal-title":"Genet Med"},{"issue":"1","key":"949_CR176","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40271-022-00589-5","volume":"16","author":"H Gelhorn","year":"2023","unstructured":"Gelhorn H, Ross MM, Kansal AR, et al. Patient preferences for multi-cancer early detection (MCED) screening tests. Patient. 2023;16(1):43\u201356.","journal-title":"Patient"},{"issue":"3","key":"949_CR177","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12687-022-00590-3","volume":"13","author":"MW Hardy","year":"2022","unstructured":"Hardy MW, Peshkin BN, Rose E, et al. Attitudes and interest in incorporating BRCA1\/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women. J Community Genet. 2022;13(3):281\u201392.","journal-title":"J Community Genet"},{"issue":"1","key":"949_CR178","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40273-019-00834-0","volume":"38","author":"DA Regier","year":"2020","unstructured":"Regier DA, Veenstra DL, Basu A, et al. Demand for precision medicine: a discrete-choice experiment and external validation study. Pharmacoeconomics. 2020;38(1):57\u201368.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"949_CR179","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40271-020-00448-1","volume":"14","author":"S Costa","year":"2021","unstructured":"Costa S, Regier DA, Raymakers AJN, et al. Genomic testing for relapsed and refractory lymphoid cancers: understanding patient values. Patient. 2021;14(2):187\u201396.","journal-title":"Patient"},{"issue":"1","key":"949_CR180","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/jgc4.1455","volume":"31","author":"P Butow","year":"2022","unstructured":"Butow P, Davies G, Napier CE, et al. Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. J Genet Couns. 2022;31(1):96\u2013108.","journal-title":"J Genet Couns"},{"issue":"2","key":"949_CR181","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2217\/pme-2021-0067","volume":"19","author":"K Clasen","year":"2022","unstructured":"Clasen K, Gani C, Schroeder C, et al. Patient views on genetics and functional imaging for precision medicine: a willingness-to-pay analysis. Pers Med. 2022;19(2):103\u201312.","journal-title":"Pers Med"},{"issue":"1","key":"949_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40661-019-0066-8","volume":"6","author":"BA Davidson","year":"2019","unstructured":"Davidson BA, Ehrisman J, Reed SD, et al. Preferences of women with epithelial ovarian cancer for aspects of genetic testing. Gynecol Oncol Res Pract. 2019;6(1):1.","journal-title":"Gynecol Oncol Res Pract."},{"issue":"6","key":"949_CR183","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/jpm12060879","volume":"12","author":"S Fifer","year":"2022","unstructured":"Fifer S, Ordman R, Briggs L, et al. Patient and clinician preferences for genetic and genomic testing in non-small cell lung cancer: a discrete choice experiment. J Pers Med. 2022;12(6):879.","journal-title":"J Pers Med."},{"issue":"9","key":"949_CR184","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41431-018-0161-z","volume":"26","author":"D Weymann","year":"2018","unstructured":"Weymann D, Veenstra DL, Jarvik GP, et al. Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment. Eur J Hum Genet. 2018;26(9):1257\u201365.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"949_CR185","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajhg.2018.11.014","volume":"104","author":"Z Stark","year":"2019","unstructured":"Stark Z, Dolman L, Manolio TA, et al. Integrating genomics into healthcare: a global responsibility. Am J Hum Genet. 2019;104(1):13\u201320.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"949_CR186","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12939-015-0208-5","volume":"14","author":"L Liaropoulos","year":"2015","unstructured":"Liaropoulos L, Goranitis I. Health care financing and the sustainability of health systems. Int J Equity Health. 2015;14(1):80.","journal-title":"Int J Equity Health."},{"issue":"4","key":"949_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102981","volume":"9","author":"T Kubo","year":"2024","unstructured":"Kubo T, Sunami K, Koyama T, et al. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology. ESMO Open. 2024;9(4): 102981.","journal-title":"ESMO Open."},{"issue":"5","key":"949_CR188","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.trecan.2020.11.002","volume":"7","author":"S Kato","year":"2021","unstructured":"Kato S, Alsafar A, Walavalkar V, et al. Cancer of unknown primary in the molecular era. Trends Cancer. 2021;7(5):465\u201377.","journal-title":"Trends Cancer."},{"key":"949_CR189","unstructured":"Tripp S, Grueber M. The economic impact and functional applications of human genetics and genomics. American Society of Human Genetics; 2021. https:\/\/www.ashg.org\/wp-content\/uploads\/2021\/05\/ASHG-TEConomy-Impact-Report-Final.pdf."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00949-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-025-00949-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00949-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T10:03:55Z","timestamp":1746439435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-025-00949-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":189,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["949"],"URL":"https:\/\/doi.org\/10.1007\/s40258-025-00949-w","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"19 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cancer Australia and the World Health Organization funded this work, which informed part of an evidence review commissioned by Cancer Australia and has been expanded by the World Health Organization with support from the National Institutes of Health\u00a0under award number 5U01AI139547-05. Aideen McInerney-Leo is funded by a University of Queensland Faculty of Medicine Fellowship. Julia Steinberg is supported by a Cancer Institute NSW Career Development Fellowship (2022\/CDF1154). Tiffany Boughtwood as part of Australian Genomics received funding from the following grants in this timeline\u00a0NHMRC GNT2000001 and GNT2035846.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mackenzie Bourke, Aideen McInerney-Leo, Julia Steinberg, Tiffany Boughtwood, Vivienne Milch, Anna Laura Ross, Elena Ambrosino, Kim Dalziel, Fanny Franchini, Li Huang, Riccarda Peters, Francisco Santos Gonzalez and Ilias Goranitis have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data used to generate this review are available online from the references provided. Data extracted are presented in the article and the supplementary Appendix.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were conducted by MB, RP, FSG and IG. The first draft and subsequent drafts of the manuscript were written by MB. All authors were responsible for comments on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}